



Stimunity is laureate of the i-Lab 2017 national competition

Paris, July 10, 2017 -- Stimunity is pleased to announce that the company is laureate of the i-Lab 2017 national competition in the pharmaceutical and biotechnology sector, and receives 200k€ as a non-dilutive financing.

I-Lab national competition selects the best innovative and promising startup companies all over the French territory and in multiple sectors. 60% of the projects are issued from academia and are based on solid scientific background. In this 2017 edition, 400 applications were received for 62 laureates (15% ratio selection), and 12 laureates in the biotechnology sector. In addition to the label given by this tough competition, each laureate receives an average of 150k€ as non-dilutive financing. The projects were selected first on a written proposal, then audited by Ernst & Young on the feasibility of the business plan, and nominated by a double regional and national jury.

Stimunity also receives 200k€ as non-dilutive financing which will help to launch the company in the early stage. "This is a key step for us as this grant will help us to reinforce our preclinical efficacy package and de-risking our project. This is critical if we want to be in a good position to raise our first seed round of investment" says Sylvain Carlioz, CEO and cofounder of the company.

About i-Lab



I-LAB was born of the impulsion of the Ministry of Higher Education, Research and Innovation to reinforce the support of innovative startup companies and encourage the entrepreneurial spirit, particularly among researchers and young people in higher education and academia. Since its creation, 19 years ago, the competition achieved:

- The creation of 1,828 companies, of which 70% are still active and continue to grow. Some have become worldwide leader in their field of activity;
- More than 50% of these companies come from public research;
- 21 733 applications, 3 348 laureates and 1 828 startup companies created;
- In total, more than 400 M€ invested as non-dilutive financing;



More information at:

- <http://www.enseignementsup-recherche.gouv.fr/cid118485/concours-i-lab-2017-62-laureat.e.s-representant-l-excellence-de-l-entrepreneuriat-francais.html>
- https://cache.media.enseignementsup-recherche.gouv.fr/file/actu_innovation/09/6/livret-palmares-ilab2017_793096.pdf

About Stimunity



Stimunity is a startup company from Institut Curie which develops biopharmaceuticals to treat patients that still do not respond to conventional immunotherapy in infectious disease and cancer. Stimunity focuses on the STING pathway, which is known to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells. By addressing this target with a unique biologic approach which combines the the endogenous STING activator encapsulated in a Virus-Like Particle (VLP), Stimunity's drugs are best-in-class.

More information at <http://stimunity.com> or contact@stimunity.com.
